At ADC Therapeutics, we strive to transform the lives of those impacted by cancer by unlocking the potential value of our focused ADC portfolio.
Science
Our technology includes an FDA-approved anti-CD19 ADC, and a next-generation PSMA-targeting ADC in development which utilizes a differentiated exatecan-based payload with a novel hydrophilic linker.
We are seeking expansion of our FDA-approved product, ZYNLONTA®(loncastuximab tesirine-lpyl), while advancing IND-enabling activities for our early-stage PSMA-targeting ADC.
Medical Affairs
We aim to confront unmet medical needs in patients with hematologic cancers and solid tumors. With cancers that recur or are refractory as well as treatments that do not produce durable and complete responses, patients are in need of new approaches to cancer therapy.
Proven Momentum
ZYNLONTA® is a prescription medicine currently approved to treat adults with certain types of large B-cell lymphoma that has come back (relapsed) or that did not respond to previous treatment (refractory), who have already received two or more treatments for their cancer.
